Three new cancer-fighting medicines called antibody-drug conjugates are now approved to treat ovarian and cervical cancers in women whose cancers haven’t responded to standard treatments. According to Gram Research analysis, these medicines work like guided missiles—they find cancer cells and deliver powerful drugs directly to them, potentially causing fewer side effects than traditional chemotherapy. Researchers are exploring ways to make these medicines even more effective by combining them with other therapies.
Scientists have developed a new type of medicine called antibody-drug conjugates (ADCs) that work like guided missiles—they find cancer cells and deliver powerful drugs directly to them. According to Gram Research analysis, three of these medicines are now approved to treat ovarian and cervical cancers in women who haven’t responded to other treatments. These drugs target specific markers on cancer cells, making them more effective while causing fewer side effects than traditional chemotherapy. Researchers are now exploring how to combine these medicines with other treatments to make them even more powerful and help more patients.
Key Statistics
A 2026 review in Nature Reviews Clinical Oncology identified three antibody-drug conjugates currently approved for gynecological cancers: mirvetuximab soravtansine for ovarian cancer, trastuzumab deruxtecan for HER2-positive solid tumors, and tisotumab vedotin for cervical cancer.
Research shows that combining antibody-drug conjugates with immune checkpoint inhibitors may amplify the body’s anti-tumor immunity and extend how long treatment benefits last in gynecological cancer patients.
According to a 2026 clinical review, antibody-drug conjugates represent a significant advancement in cancer treatment over the past two decades, transforming therapeutic outcomes across multiple cancer types including women’s cancers.
The Quick Take
- What they studied: How a new class of cancer medicines called antibody-drug conjugates work against women’s cancers, what they can do, and what challenges doctors still need to solve.
- Who participated: This is a review article that examined existing research and clinical trials on three approved medicines for ovarian and cervical cancers, rather than conducting a new study with patients.
- Key finding: Three new medicines are now approved for treating ovarian and cervical cancers in women whose cancers didn’t respond to standard treatments, and researchers are finding ways to make them work even better by combining them with other therapies.
- What it means for you: If you or someone you know has ovarian or cervical cancer that hasn’t responded to standard treatment, these new medicines may offer additional options. Talk with your cancer doctor about whether you might be a candidate for these newer treatments.
The Research Details
This is a review article, which means researchers looked at all the existing scientific studies and clinical trials about antibody-drug conjugates in women’s cancers rather than conducting their own new experiment. The authors examined how these medicines work, which ones are currently approved, what results they’ve shown in patients, and what challenges remain.
Antibody-drug conjugates are a special type of medicine that combines two parts: an antibody (a protein that finds cancer cells) and a powerful drug (that kills the cancer). Think of it like a delivery truck—the antibody is the truck that finds the right address (the cancer cell), and the drug is the package it delivers. This approach helps the medicine find cancer cells while avoiding healthy cells.
The review focused on three medicines that are now approved: mirvetuximab soravtansine for ovarian cancer, trastuzumab deruxtecan for solid tumors, and tisotumab vedotin for cervical cancer. Researchers also looked at how these medicines might work better when combined with other treatments, particularly immune-boosting therapies.
This research matters because it helps doctors and patients understand what new treatment options exist for cancers that are difficult to treat. By reviewing all the available evidence, the researchers can identify which medicines work best, what side effects to watch for, and how to use them most effectively. This type of review also helps identify gaps in our knowledge—areas where more research is needed.
This is a review article published in a highly respected medical journal (Nature Reviews Clinical Oncology), which means it was written by expert researchers and reviewed by other experts before publication. However, because it’s a review rather than a new study, it summarizes other people’s research rather than presenting original data. The strength of the conclusions depends on the quality of the studies being reviewed. The authors appear to have comprehensively examined the current state of knowledge about these medicines.
What the Results Show
Three antibody-drug conjugates are currently approved for treating women’s cancers that have not responded to standard treatments. Mirvetuximab soravtansine targets ovarian cancers that have a specific marker called folate receptor-alpha. Trastuzumab deruxtecan works against solid tumors with high levels of a protein called HER2. Tisotumab vedotin treats cervical cancer regardless of whether it has a specific marker called tissue factor.
These medicines have shown promising results in clinical trials, helping some patients whose cancers had stopped responding to other treatments. The key advantage is that these drugs are designed to specifically target cancer cells while minimizing damage to healthy cells, which can reduce side effects compared to traditional chemotherapy.
Researchers are also finding that combining these medicines with immune checkpoint inhibitors—drugs that help the body’s immune system fight cancer—may make them even more effective. These combinations appear to help the body maintain its cancer-fighting response for longer periods.
The review identifies several important challenges that doctors and researchers are working to solve. One challenge is understanding why some patients’ cancers become resistant to these medicines over time. Another is figuring out the best order to use different treatments and how to manage side effects. Researchers are also looking for new cancer cell markers that these medicines could target, which would expand treatment options for more patients.
Antibody-drug conjugates represent an evolution in cancer treatment that has been developing over the past 20 years. These medicines build on earlier discoveries about how to target cancer cells more precisely. The approval of three different ADCs for women’s cancers shows that this approach is becoming more established and accepted as a standard treatment option, similar to how other targeted therapies have become routine in cancer care.
This is a review article, so it doesn’t present new patient data. The conclusions are only as strong as the individual studies being reviewed. Some of the medicines discussed are relatively new, so long-term safety and effectiveness data are still being collected. Additionally, these medicines are currently only approved for patients whose cancers have already been treated with other therapies, not as first-line treatments. More research is needed to understand how to best combine these medicines with other treatments and how to predict which patients will benefit most.
The Bottom Line
For patients with ovarian or cervical cancer that hasn’t responded to standard treatments: Ask your oncologist whether you might be eligible for one of these newer antibody-drug conjugate medicines. The evidence supporting these treatments is strong enough that they are now approved by regulatory agencies. For researchers and doctors: Continue investigating how to combine these medicines with other therapies and how to identify patients most likely to benefit.
Women with ovarian or cervical cancer that has progressed despite standard treatment should discuss these options with their cancer specialists. Healthcare providers treating gynecological cancers should be aware of these approved options. Researchers developing new cancer treatments should consider how antibody-drug conjugates might be applied to other cancers. People with family histories of these cancers may want to stay informed about emerging treatments.
Patients who receive these medicines may see initial responses within weeks to months, though individual responses vary significantly. Some patients experience long-lasting benefits, while others may develop resistance over time. It typically takes several months to fully assess whether a treatment is working effectively.
Frequently Asked Questions
What are antibody-drug conjugates and how do they treat cancer?
Antibody-drug conjugates are medicines that combine an antibody (which finds cancer cells) with a powerful drug (which kills them). They work like guided missiles, targeting cancer cells specifically while avoiding healthy cells, which reduces side effects compared to traditional chemotherapy.
Are these new cancer medicines approved for ovarian and cervical cancer?
Yes, three antibody-drug conjugates are currently approved for women’s cancers: mirvetuximab soravtansine for ovarian cancer, trastuzumab deruxtecan for certain solid tumors, and tisotumab vedotin for cervical cancer. These are approved for patients whose cancers haven’t responded to standard treatments.
Can antibody-drug conjugates be combined with other cancer treatments?
Research shows that combining antibody-drug conjugates with immune checkpoint inhibitors—drugs that boost the body’s immune system—may make them more effective and help treatment benefits last longer. Doctors are actively studying these combinations.
What are the main challenges with antibody-drug conjugates?
Key challenges include understanding why some cancers become resistant to these medicines, managing side effects, determining the best order to use different treatments, and identifying which patients will benefit most. Researchers are actively working to solve these problems.
Who should consider antibody-drug conjugate treatment?
Women with ovarian or cervical cancer that hasn’t responded to standard treatments should discuss these options with their cancer doctor. These medicines are currently approved for previously treated cancers, not as first-line treatments.
Want to Apply This Research?
- If using one of these medicines, track weekly: energy levels (1-10 scale), any new side effects or changes in existing side effects, and appointment dates with your oncology team. Log any questions or concerns to discuss at your next visit.
- Set reminders for all scheduled infusions and follow-up appointments. Create a side effect log to share with your medical team, noting when side effects occur and their severity. This helps your doctor adjust your treatment plan if needed.
- Maintain a monthly summary of your treatment response, side effects, and quality of life measures. Share this with your oncology team at each visit. Track any changes in symptoms that might indicate the cancer is responding or progressing. Keep records of all medications and supplements you’re taking to discuss potential interactions.
This article reviews scientific research about antibody-drug conjugates for gynecological cancers. It is not a substitute for professional medical advice. If you have ovarian or cervical cancer or are concerned about your cancer treatment options, consult with your oncologist or healthcare provider. Treatment decisions should be made in consultation with qualified medical professionals who understand your individual medical history and circumstances. The approval status and availability of these medicines may vary by country and change over time.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.